AstraZeneca Articles
AstraZeneca CEO to go early, as 1st-qtr sales and profits plunge; makes deal with TMC for cardiovasculars
26 April 2012
AstraZeneca to acquire Ardea Bio for $1.26 billion
23 April 2012
Daiichi Sankyo debuts bone cancer drug Ranmark in Japan
17 April 2012
AstraZeneca in NMR collaborative deal with Conformetrix
16 April 2012
AstraZeneca collaborates with Amgen on five MAbs
3 April 2012
Teva debuts generic of Provigil, Avapro and Avalide; Ranbaxy Crestor copy OKed in Canada
1 April 2012
US Court upholds AstraZeneca Seroquel XR patent
30 March 2012
Gap in patent filings for biological and small-molecule drugs widening, says Withers & Rogers
20 March 2012
AstraZeneca sues US FDA over Seroquel decision
13 March 2012
AstraZeneca Seroquel petitions denied by US FDA
9 March 2012
FDA expands on cholesterol-lowering drug risks
29 February 2012
Nine news Rx drugs added to Australian PBS listings
22 February 2012
EU approval for AstraZeneca thyroid cancer drug Caprelsa
21 February 2012
AstraZeneca offering Arimidex for just $40 a month in USA
16 February 2012
AstraZeneca profits rise, but more jobs to go
2 February 2012
Impax buys US rights to Zomig
1 February 2012
FDA’s CRL on dapagliflozin calls for more clinical data
19 January 2012
Japanese approval for Regnite and Ranmark
18 January 2012
AstraZeneca links with IMS on real-world evidence
11 January 2012
Double R&D setback for AstraZeneca; new deal for cancer candidate
21 December 2011
Brilique first drug to gain post-AMNOG decision in Germany
16 December 2011
Mixed NICE views on Faslodex and RoActemra
14 December 2011
AstraZeneca sells imaging agent rights
13 December 2011
AstraZeneca expands in China, cuts back in USA
8 December 2011
AstraZeneca unlocks medical research cupboard to academia, as UK plans boost for pharma sector
5 December 2011
Brazilian acute coronary syndrome drug market set to nearly double to $229 million in 2015
1 December 2011
Further $100 million committed to AstraZeneca’s MedImmune Ventures
29 November 2011
EC approves additional use for Bristol-Myers and AstraZeneca’s Onglyza and Komboglyze
29 November 2011
China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015
22 November 2011
EU Pharma re-rating stalled against EU market vis-a-vis defensives, says Nomura analyst
13 November 2011
UK’s NICE says no to AstraZeneca breast cancer drug Faslodex
10 November 2011
Disappointment for AstraZeneca and Targacept as antidepressant fails to meet Ph III endpoint
9 November 2011
AstraZeneca launches new Crestor savings card in USA, as generic Lipitor about to debut
7 November 2011
AgonOx partners with AstraZeneca unit for development of OX40 agonists in cancer therapy
2 November 2011
European oncologists indicate Tarceva will threaten market position of Iressa in mutated EGFR NSCLC
2 November 2011
Sunovion’s Latuda non-inferior to AstraZeneca’s Seroquel XR in risk relapse for schizophrenia patients
30 October 2011
AstraZeneca and B-MS see delay for dapagliflozin, as AZ posts 3rd-qtr 2011 results with generics taking a toll
27 October 2011
AstraZeneca’s blood thinner Brilinta/Brilique demonstrates cost effectiveness; new Nexium indication filed in Japan
24 October 2011
AstraZeneca and Forest initiate Ph III trials of CAZ-AVI
18 October 2011
AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza
10 October 2011
AstraZeneca in two more Seroquel XR patent settlements; Actavis outlines South America aims
6 October 2011
AstraZeneca’s Brilique first to be assessed under Germany’s AMNOG, getting positive view
5 October 2011
AstraZeneca in patent settlement deal with Handa over Seroquel XR
30 September 2011
Approval of diabetes drugs from AstraZeneca/B-MS and Novo Nordisk supported by EU’s CHMP; Faslodex cleared in Japan
26 September 2011
AstraZeneca/MedImmune’s tralokinumab shows positive impact on pulmonary function in patients with uncontrolled asthma
19 September 2011
Ranbaxy debuts first approved generic of Nexium in the UK
5 September 2011
Trudeau Institute discovers how FluMist elicits protection
24 August 2011
AstraZeneca breast cancer drug Faslodex not good use of NHS resources, says NICE draft guidance
24 August 2011
AstraZeneca blood thinner Brilinta now available in USA
23 August 2011
US FDA advisory gives thumbs down to B-MS and AstraZeneca diabetes drug dapagliflozin on safety issues
20 July 2011
Pharma’s differentiated strategies for evolving health care landscape presented at Nomura conference
5 July 2011
AstraZeneca gets UK NICE backing for Brilique; collaborates with PTC for oncology and other potential drugs
30 June 2011
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
